Diagenode announces acquisition of Service Provider NXT-Dx to complement Epigenetics Assay Services

Denville, USA and Liege, Belgium: 16 August 2018 - Diagenode today announced the acquisition of NXT-Dx, an established epigenetics service provider based in Gent, Belgium. NXT-Dx provides a broad variety of start-to-finish epigenetics services including a number of targeted DNA methylation assays using pyrosequencing or Next-Generation Sequencing and Illumina's Infinium Methylation EPIC array. These technologies enable a more targeted approach for the screening of DNA methylation biomarkers. In addition, NXT-Dx offers chromatin and mRNA wet-lab and analysis services.

More info on Diagenode's website.

Next > Mainstay Medical announces the appointment of Matthew Onaitis as Chief Financial Officer

Previous > Nexstim Plc half-yearly report 1 January – 30 June 2018 (Unaudited)